𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

✍ Scribed by Gabrielle van der Velde; Ba' Pham; Márcio Machado; Luciano Ieraci; William Witteman; Claire Bombardier; Murray Krahn

Publisher
Wiley (John Wiley & Sons)
Year
2010
Tongue
English
Weight
172 KB
Volume
63
Category
Article
ISSN
2151-464X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of biologics in polya
Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs
✍ Wendy J. Ungar; Vania Costa; Rebecca Hancock-Howard; Brian M. Feldman; Ronald M. 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 150 KB 👁 2 views

## Abstract ## Objective Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease and can have long‐term effects leading to disability in adulthood. Biologics are a new class of drugs increasingly used to treat JIA. The primary study objective was to determine the

American College of Rheumatology 2008 re
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
✍ Saag, Kenneth G. ;Teng, Gim Gee ;Patkar, Nivedita M. ;Anuntiyo, Jeremy ;Finney, 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 2 views

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be v

Comparison of the response to infliximab
Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register
✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods